Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
08 avr. 2024 11h36 HE
|
Revolution Medicines, Inc.
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...
Revolution Medicines to Participate in Upcoming Investor Conferences
04 avr. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024
03 avr. 2024 06h30 HE
|
Aanastra Inc
Aanastra to present its RNA peptide therapeutics technology at AACR conference
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
28 mars 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Janus Kinase (JAK) Inhibitor Market Forecast 2024-2034: Analyzes Trends Likely to Shape Future Opportunities
14 mars 2024 04h30 HE
|
Research and Markets
Dublin, March 14, 2024 (GLOBE NEWSWIRE) -- The "Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ...
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
06 mars 2024 16h05 HE
|
Cardiff Oncology, Inc.
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Sphingosine 1 Phosphate Receptor Modulators Market Size, Target Population, Competitive Landscape & Forecasts, 2020-2023 and 2024-2034: Focus on US, Germany, France, Italy, Spain UK, and Japan
01 mars 2024 09h31 HE
|
Research and Markets
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Sphingosine 1 Phosphate Receptor (S1PR) Modulators Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been...
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
26 févr. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
20 févr. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Participate in Upcoming Investor Conferences
01 févr. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...